US FDA extends review of Capricor's muscle disorder therapy by three months
24/08/2026 14:27
US FDA extends review of Capricor's muscle disorder therapy by three months Aug 24 (Reuters) - Capricor Therapeutics CAPR.O said on Monday that the U.S. Food and Drug Administration had extended the review of its experimental cell therapy for Duchenne muscular dystrophy by three months.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shinjini Ganguli)